Gene therapies set to revolutionise cardiovascular treatments
Gene therapies could revolutionise management of cardiovascular diseases such as heart failure, according to a GlobalData report.
List view / Grid view
Gene therapies could revolutionise management of cardiovascular diseases such as heart failure, according to a GlobalData report.
A new US study demonstrated that comprehensive genomic sequencing is crucial for the development of precision medicine for cancer patients.
Researchers have developed a novel gene therapy that could help treat children with incurable genetic and neurodegenerative diseases.
To promote the safe and ethical use of genome editing for the treatment of disease and genetic disorders WHO has published the first global recommendations.
The collaborative work has produced the largest browsable resource linking rare protein-coding genetic variants to human health and disease that will accelerate targeted drug development.
Asymptomatic and symptomatic children treated with Zolgensma® (onasemnogene abeparvovec) gene therapy achieved motor milestones never observed in the natural history of spinal muscular atrophy.
The betibeglogene autotemcel (beti-cel) gene therapy caused paediatric and adult beta thalassaemia patients to achieve transfusion independence lasting over two years.
In a Phase II trial, injecting GAD-alum into the lymph nodes of newly diagnosed type 1 diabetes patients with a genetic variant slowed insulin production degradation.
In this article, experts from Charles River Associates discuss how the introduction of cell and gene therapies will impact upon various aspects of the healthcare system, from provision of care to delivery and supply, and pricing and market access.
In three Phase I/II trials an experimental gene therapy caused all but two patients with severe combined immunodeficiency to acquire and retain robust immune function for more than two years.
In this article, Liz Thorn, Senior Consultant, Diagnostics at Team Consulting, explores the various in vitro diagnostics (IVDs) techniques available and where they are best applied in the context of influenza and COVID-19.
According to a new study, Drug Ranking Using Machine Learning (DRUML) can accurately rank cancer therapies by efficacy across a range of cancer types.
Data from nearly seven years of follow up suggests one-time treatment with eli-cel may durably stabilise cerebral adrenoleukodystrophy disease progression.
The novel, non-invasive test detects a rejection signature within mRNA isolated from urine and could, with further development, be used instead of biopsies to identify transplant rejection.
The DECODR app was developed to accelerate the development of CRISPR gene therapies, producing similar data as deep sequencing processes in a shorter timeframe and at less cost.